Open-Label Treatment for Patients Completing Study B7A-MC-MBCM
Open-Label Treatment for Patients Completing Study B7A-MC-MBCM
To provide ruboxistaurin treatment to patients who completed the B7A-MC-MBCM study (NCT00604383), and who are felt by the investigator to have the potential to benefit from the ruboxistaurin treatment. Patients must be off study drug for 6 to 18 months from completion of B7A-MC-MBCM before beginning B7A-MC-MBDV. Additional data will be gathered to determine the long-term safety and effect of ruboxistaurin on vision.
Inclusion Criteria:
Exclusion Criteria:
Mesa, Arizona 85210, United States
Phoenix, Arizona 85014, United States
Huntington Beach, California 92647, United States
Orange, California 92868, United States
Sacramento, California 95817, United States
Hamden, Connecticut 06518, United States
Newark, Delaware 19713, United States
Tampa, Florida 33609, United States
Honolulu, Hawaii 96813, United States
Wheaton, Illinois 60187, United States
Indianapolis, Indiana 46280, United States
Shawnee Mission, Kansas 66204, United States
Baltimore, Maryland 21287, United States
Towson, Maryland 21204, United States
Boston, Massachusetts 02215, United States
Grand Rapids, Michigan 49525, United States
Royal Oak, Michigan 48073, United States
Columbia, Missouri 65212, United States
Staten Island, New York 10305, United States
Charlotte, North Carolina 28210, United States
Beachwood, Ohio 44122, United States
Cincinnati, Ohio 45242, United States
Hershey, Pennsylvania 17033, United States
Pittsburgh, Pennsylvania 15213, United States
Columbia, South Carolina 29203, United States
Rapid City, South Dakota 57701, United States
Dallas, Texas 75231, United States
Salt Lake City, Utah 84107, United States